1. Home
  2. MDGL vs BIO Comparison

MDGL vs BIO Comparison

Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$554.51

Market Cap

12.8B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

HOLD

Current Price

$317.93

Market Cap

8.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDGL
BIO
Founded
2011
1952
Country
United States
United States
Employees
N/A
7450
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
8.0B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
MDGL
BIO
Price
$554.51
$317.93
Analyst Decision
Strong Buy
Buy
Analyst Count
12
4
Target Price
$674.45
$339.75
AVG Volume (30 Days)
280.1K
270.6K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
41.32
N/A
EPS
N/A
N/A
Revenue
$180,133,000.00
N/A
Revenue This Year
$58.39
$2.74
Revenue Next Year
$48.55
$3.20
P/E Ratio
N/A
$9.72
Revenue Growth
N/A
N/A
52 Week Low
$286.75
$236.73
52 Week High
$615.00
$343.12

Technical Indicators

Market Signals
Indicator
MDGL
BIO
Relative Strength Index (RSI) 58.46 66.97
Support Level $529.02 $296.46
Resistance Level $570.82 $325.65
Average True Range (ATR) 20.46 8.51
MACD -0.57 2.03
Stochastic Oscillator 67.29 97.57

Price Performance

Historical Comparison
MDGL
BIO

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: